Brought to you by 
GE Healthcare and Geron collaborate on cellular assays
24 Oct 2012
Executive Summary
In a multi-year deal, scientists from GE Healthcare and Geron (developing telomerase-targeting cancer candidates and cell therapeutics) will work on cellular assays derived from NIH-approved human embryonic stem cell (hESC) lines listed on the Human Pluripotent Stem Cell Registry.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GE Healthcare and Geron collaborate on cellular assays
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice